January 1, 1987

A Study of Learning Strategies in Foreign Language Instruction. First Year Report.

Key Points

Key points are not available for this paper at this time.

Abstract

In first individual cases, iRIT with 177LuLu-6A10-Fab appears to be feasible and safe, without therapy-related side effects. A confirmatory multicenter phase-I-trial was recently opened and is currently recruiting.

Mark Helpful

Bookmark

Relay

Cite This Study

Anna Uhl Chamot (Thu,) studied this question.

synapsesocial.com/papers/6a1061cb4fb650da4fff6302 https://doi.org/https://doi.org/10.1186/s13550-023-01029-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.2005 · 95 citations
2Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.2004 · 73 citations
3Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.2006 · 51 citations
4Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.1998 · 195 citations
5Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.1999 · 44 citations

Mark Helpful

Bookmark

Relay